Source: http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s-0316-rpt0263-toc.htm
Timestamp: 2014-07-23 05:47:13
Document Index: 433915660

Matched Legal Cases: ['§160', '§169', '§172', '§173', '§182', '§182', '§182', '§184', '§184', '§184']

RPT 263
Letter from CFSAN to Nutrition 21
New Dietary Ingredient Notification for Arginine Silicate Inositol (ASI) Complex
Appendix 1 - Product Specifications and Certificates of Analysis
Adams, M.R.; Forsyth, C.J.; Jessup, W.; Robinson, J.; Celermajer, D.S. 1995. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll Cardiol 26(4):1054-1061.
Adams, M.R.; McCredie, R.; Jessup, W.; Robinson, J.; Sullivan, D.; Celermajer, D.S. 1997. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 129(2):261-269.
Aeschbacher, H.U.; Chapple, C.; Manganal, M.; Aeschbacher, R. 1981. Investigation of Maillard products in bacterial mutagenicity test systems. Prog Food Nutr Sci 5279-294.
Aji, W.; Ravalli, S.; Szabolcs, M.; Jiang, X.C.; Sciacca, R.R.; Michler, R.E.; Cannon, P.J. 1997. L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation 95(2):430-437.
Barak, Y.; Levine, J.; Glasman, A.; Elizur, A.; Belmaker, R.H. 1996. lnositol treatment of Alzheimer’s disease: A double blind, cross-over placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 20(4):729-735.
Barbul, A. 1986. Arginine: biochemistry, physiology, and therapeutic implications. JPEN J Parenter Enteral Nutr 10(2):227-238. Cited In: FASEB, 1992.
Barbul, A.; Lazarou, S.A.; Efron, D.T.; Wasserkrug, H.L.; Efron, G. 1990. Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery 108(2):331-336 & Discussion, pp. 336-337. Cited In: FASEB, 1992.
Benjamin, J.; Levine, J.; Fux, M.; Aviv, A.; Levy, D.; Belmaker, R.H. 1995. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 152(7):1084-1086.
Brusilow, S.W.; Horwich, A.L. 1989. Urea cycle enzymes. b: Striver CR.; Beaudet, A.L.; Sly, W.S.; Valle, D. (Eds.). The Metabolic Basis of Inherited Disease (6th Ed.). McGraw Hill, Inc.; New York, pp. 629-663. Cited In: FASEB, 1992.
Chan, J.R.; Boger, R.H.; Bode-Bbger, S.M.; Tangphao, 0.; Tsao, P.S.; Blaschke, T.F.; Cooke, J.P. 2000. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vast Biol 20(4):1040-1046.
Cheng, J.W.M.; Baldwin, S.N. 2001. L-arginine in the management of cardiovascular diseases. Ann Pharmacother 35(6):755-764 [Erratum, 35(7&8):965].
Colodny, L.; Hoffman, R.L. 1998. Inositol--clinical applications for exogenous use. Altern Med Rev 3(6):432-447.
Devine, J. (Jr.). 2003. An Acute Oral Limit Test of Arginine Silicate lnositol Complex in the Rat: Final Report of the Study [Confidential]. BAS; Evansville. [Study No. 743A-101-010-03].
Drago, F.; Continella, G.; Alloro, M.C.; Auditore, S.; Pennisi, G. 1984. Behavioral effects of arginine in male rats. Pharmacol Res Commun 16(9):899-907.
Edmonds, M.S.; Gonyou, H.W.; Baker, D.H. 1987. Effect of excess levels of methionine, tryptophan, arginine, lysine or threonine on growth and dietary choice in the pig. J Anim Sci 65: 179-185.
Einat, H.; Belmaker, R.H.; Kopilov, M.; Klein, E.; Gazawi, H.; Ben-Shachar, D. 1999a. Rat brain monoamines after acute and chronic myo-inositol treatment. Eur Neuropsychopharmacol 10(1):27-30.
Einat, H.; Karbovski, H.; Korik, J.; Tsalah, D.; Belmaker, R.H. 1999b. Inositol reduces depressive-like behaviors in two different animal models of depression. Psychopharmacology 144(2):158-162.
FASEB. 1992. Safety of Amino Acids Used in Dietary Supplements. Prepared by: U.S. Food and Drug Administration (U.S. FDA), Center for Food Safety and Applied Nutrition (CFSAN); Washington, DC for Life Sciences Research Office (LSRO), Federation of American Societies for Experimental Biology (FASEB); Bethesda, Maryland.
FDA. 1993. Priority Based Assessment of Food Additives (PAFA) Database. Food and Drug Administration (FDA), Center for Food Safety and Applied Nutrition (CFSAN); Washington, DC.
FDA. 2004. Code of Federal Regulations. Title 21 - Food and Drugs. [Parts §160.105; §169.179; §172.320; §173.310; §182.1045; §182.1711; §182.2729; §184.1370; §184.1 (b)(1); §184.1069]. Food and Drug Administration, U.S. (FDA); Washington (DC).
Gudi, R.; Krsmanovic, L. 2004. Mammalian Erythrocyte Micronucleus Test: Arginine Silicate Inositol Complex: Final Report [Confidential]. Tested by BioReliance; Rockville, Maryland, Sponsored by Nutrition 21, Inc.; Purchase, New York. [Bioreliance Study Number: AA75TT.123.BTL].
Gudi, R.; Rao, M. 2004. In Vitro Mammalian Chromosome Aberration Test: Arginine Silicate Inositol Complex: Final Report [Confidential]. Tested by BioR